Adoptions and Orphans

Posts Tagged ‘orphan’

Product Description
MOUNTAIN ORGY! Rita was just a houseguest at the Kirbys’ mountain cabin; a pleasant outing from the orphanage. Until two escaped convicts broke in?-armed to the teeth and horny as hell!

The Passionate Orphan

Adoptions And Orphans is a very complicated decision to make. It is very difficult to raise a child who is not yours biologically. It is somewhat odd for both parents to decide whether to adopt or not but most parents resort to adoption to keep the marriage intact. Some might think that parents who adopt are not secure with the relationship they have and the adoption process might throw the relationship out of balance. Well, just a trivia, a huge percentage of parents adopt every year, and yet they feel thankful for making the right decision. Here are the unconventional reasons why couples resort to orphan adoption. First reason for orphan Adoptions And Orphans is the unparalleled compassion with children. It might sound unrealistic, but it is a fact. Couples tend to adopt because they have compelling love for children. They might have past experiences for the feeling of compassion so they adopt regardless if they have natural children or not. For some couples, they tend to adopt a specified orphan like gender. A married couple has two children, and both are girls, if they adopt, they will prefer a boy to complete the family rather than taking the risk of bearing another child whose sexuality is undetermined. Another main reason for adopting involves a single person who would want to experience how to be a parent. Most of the women nowadays are practical. Some doesn’t want to marry, or to have a partner in life, but they are dying for a child so, they decide to adopt. As how the famous Miss Universe Sushmita Sen puts it, “The child needed a parent, and I needed a child”. Single ladies adopt to experience parenthood, and I think they find satisfaction in rearing a child even though those kids didn’t come from their womb. Being the only child in the family is lonely. You play, study, and do things alone. Some kids ask for a companion, a friend, a brother or a sister. The parent, eventually will realize the need to adopt. It’s much easier to adopt and have another child and complete the family, than to bear another child and take the risk. Well, it’s more of satisfying a request from the only child at the same time fulfilling a concept of a complete family. Convenience is also a factor. Married couples who are indulge with their careers have no time for the childbirth process itself. They find it convenient to adopt, to fulfill a complete family. For career-oriented couples, they don’t want so much complication while keeping the relationship intact. Lastly, for couples who will go with orphan adoption although they have the capability to raise their own is some kind of “laziness”. As what have said, they hate complications. They would want to experience parenthood in an easy way. Adoptions And Orphans might sound simple and easy, but the reasons are deeper than what we expect it to be. The process itself is so complex and risky. There’s nothing wrong with orphan adoption, but bear in mind the consequences after it and the risk that you have to take in rearing the child that is not Ask yourself the question “what if it turns to worse”?

The U.S. Citizenship and Immigration Services (USCIS) had announced on April 1, 2010, the centralization of processing and adjudication of all new orphans’ (Non-Hague) petitions with the agency’s specific adoptions team in Missouri. The filing of petition to classify orphan as an immediate relative (Form I 600) and application for advance processing of orphan Petition (Form I 600A) by prospective parents will be accepted at the USCIS’ Dallas Lockbox facility. The file will be forwarded to the Orphan Unit at USCIS’ National Benefit Center (NBC) by the USCIS’ Dallas Lockbox facility for processing and adjudication of the case. The USCIS’ Dallas Lockbox facility will send a receipt notice with the NBC address and contact information to the applicant for further proceedings and contacts.

The prior mentioned proceedings will enable USCIS to take immediate course of action for processing of the application and petition. This course of action will also allow the USCIS to streamline and regulate the work processes. Such measures are taken intending the benefit of the parents involved in orphan adoption. Based on the NBC’s implementation of the USCIS Hague Adoption Convention program in 2008; the parents who intend orphan adoption are benefited by experiencing the specialized skills of the NBC Non-Hague Adoption Unit.

Requests to extend and change circumstances for the approval of Form I-600A will be accepted at the Local USCIS field offices in the USA, in relevance to the current filing instructions.

Overseas U.S. citizens involved in orphan adoption can continue to file Form I-600A at a U.S. Embassy or Consulate abroad, which has the legal rights to accept the petition. However the petitioner involved in orphan adoption abroad, should be physically present in the adoptive child’s country and have an approved Form I-600A. Citizens of the United States living abroad can continue to file the Form I-600A with an overseas USCIS office or the Dallas Lockbox facility.

For further clarifications in orphan adoption, the interested prospective parents or guardians can go through http://www.uscis.gov/adoptions.

Increasingly prevalent among the problems that beset the continent of Africa is rising morbidity as a consequence of HIV/AIDS, and the impact this is having on generations of children, from new born to adulthood.

The term ‘AIDS orphan’, coined perhaps 10 years ago describes a child below the age of 15 who has lost one of more parents as a result of HIV/AIDS. Richard Stearns, CEO of World Vision said:

“….I believe that this could very well be looked on as the sin of our generation . . . and our children 40 or 50 years from now will ask ‘what did you do while 40 million children became orphans in Africa?’ “

Recent statistics issued by UNICEF, estimate the total number of African children who may now be AIDS orphans ( a child who has lost at least one parent as a result of AIDS) to be 40 million in Africa of which 20 million live in sub-saharan Africa. These numbers are staggering and difficult to understand.

Nelson Mandela, the much loved South African humanitarian, once equated the world to a human body. He said that in the same way that a human body cannot deny the impact of gangrene in a limb, the world cannot ignore the consequences of this scourge in Africa. To do so is not just immoral, it imperils us all.

Let’s think for a moment about these millions of children. What exactly does it mean to be orphaned? The likelihood is that few of us know children who have been orphaned. Most of us may know adults whose parents have died. Many of us may have parents who have died, who we still miss daily and wish were in our lives.

If we do know orphaned children, that would likely mean we knew their parents and of the tragedy that beset them and their family, leaving a young family of orphans behind.
It is easy to imagine the grief at such a funeral service of friends and family, not just at the loss of the parents, but for the loss these children face. We would be overcome with emotions as we observed these young children during the service projecting the difficulties they must endure without their beloved parents to guide them. The poignancy of their loss would reduce most of us to tears.

Let’s take this analogy a little further. Perhaps as we think about this, we have imagined, with some relief, that the parents’ brothers and sisters, the children’s uncles and aunts are sitting next to them, and will, without thought, embrace these small children into their family. But what if this family has been so beset by tragedy that all but one of the parent’s siblings are dead and the remaining brother is mortally ill.

Perhaps then in their community, responsible citizens would look out for them? But we soon learn that the parents have left no money, they don’t own a property, and as rent will no longer be paid, the children must leave their home with immediate effect. In fact, the family only survived from the work that the parents did. Furthermore this community has been so beset with tragedy that the local school teacher, community leaders and most of the heads of the families within it are also all dead.

Their remains just the grieving mother of the children’s father, who has now buried the last of her children and must add to those other children she is already looking after, these newly orphaned children. She has little money as in the past her sons provided for her from the income they earned and now they are all dead.

While reading this, you may have been imagining a sudden death of the parents. But what if the father had lain dying an agonising death over a long period of months, even years, without the benefits of modern pain relief? The family are already exposed to increased poverty without their father’s income. Tragically, their mother is infected with the same illness as their father and although she struggles to look after her children, she soon becomes so ill she cannot leave her bed. The oldest child is 6 when his parents become very ill. Soon he is responsible for feeding his parents and his two siblings. The youngest is only 18 months old.
And now after their parents have both died within a short space of time, the youngest child is found to be infected with the same disease.

Multiply this nightmare scenario by millions.

In South Africa alone, here are an estimated 118 500 children living in 66,500 child-headed families That is families led by children from as young as ten looking after siblings and other orphaned children. HIV may be the major contributing factor to their predicament but poverty keeps them trapped in a world of destitution.

In the face of this overwhelming and mostly hidden tragedy, how can you make a difference? We must all become responsible for communicating to others the grief and sadness of so many young children losing their parents, their support networks, their chance of education. And, in so doing, spur a grassroots movement that will, at the very least bring attention to this modern tragedy.

The plight of these children needs to become an urgent issue in all governments’ agendas.

In order to raise public awareness, 29 February 2008 was dedicated the first European rare disease day (‘a rare day for very special people’), but European payers need no reminding of the significance of rare disease treatments, generally known as orphan drugs.

Eight years earlier, EU Regulation 141/2000 was enacted to encourage R&D in rare diseases and increase orphan drug output. By any standard the Regulation has been a major success. Almost 800 designation applications have been made, with 44 orphan medicines from 31 sponsoring companies receiving pan-European marketing approval. An estimated 1.6 million patients with 38 different rare diseases have potentially benefited, and the surge of interest in the area has offered hope to many more. Orphan drugs accounted for 23% of all new marketing applications to the EMEA in 2006 alone.

Rare diseases and their treatments may still be emotive territory, with a strong patient voice and genuine unmet need, but the pendulum is swinging from a guarantee of ‘special status’ when it comes to public reimbursement to issues of budgetary impact and cost effectiveness – not only because of the high cost of orphan drugs themselves, but the growing number of target diseases and treatments, associated new costs of medical education and diagnosis, and the need for chronic disease management.

Questions answered by this report include:

What is the actual in-market status of all EU designated orphan drugs with marketing authorisations up to the beginning of 2008?
Which drugs are covered by reimbursement, which are not?
Are special funds available for orphan drugs?
Where is health technology assessment required?
How large is the European price corridor for orphan drugs?
Is there a relationship between target patient population and price?
How do orphan drug policies differ across the leading European countries?
Do payers view all orphan drugs as unique?

Table of Contents :  

Executive Summary

1. Introduction
1.1 What are Orphan Drugs?
1.2 What are the P&R Issues with Orphan Drugs?

2. EU Orphan Drug Regulation
2.1 Objectives
2.2.Qualifying Criteria
2.3 Procedure/Timetable
2.4 Incentives
2.4.1 Information
2.4.2 R&D
2.4.3 Protocol Assistance
2.4.4 Marketing Approval Assistance
2.4.4.1 Priority review/fast track
2.4.4.2 Lower regulatory fees
2.4.5 Market Exclusivity
2.4.5.1 Exclusivity withdrawn?
2.5 Comparison with US Orphan Drug Act
2.6 Results
2.6.1 Designation
2.6.2 Marketing Approval
2.6.3 Medical Benefit

For more information please contact :

http://www.aarkstore.com/reports/Orphan-Drugs-in-Europe-Pricing-Reimbursement-Funding-and-Market-Access-Issues-1048.html

http://blogs.aarkstore.com/

From: Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
URL: www.aarkstore.com

In order to raise public awareness, 29 February 2008 was dedicated the first European rare disease day (‘a rare day for very special people’), but European payers need no reminding of the significance of rare disease treatments, generally known as orphan drugs.

Eight years earlier, EU Regulation 141/2000 was enacted to encourage R&D in rare diseases and increase orphan drug output. By any standard the Regulation has been a major success. Almost 800 designation applications have been made, with 44 orphan medicines from 31 sponsoring companies receiving pan-European marketing approval. An estimated 1.6 million patients with 38 different rare diseases have potentially benefited, and the surge of interest in the area has offered hope to many more. Orphan drugs accounted for 23% of all new marketing applications to the EMEA in 2006 alone.

Rare diseases and their treatments may still be emotive territory, with a strong patient voice and genuine unmet need, but the pendulum is swinging from a guarantee of ‘special status’ when it comes to public reimbursement to issues of budgetary impact and cost effectiveness – not only because of the high cost of orphan drugs themselves, but the growing number of target diseases and treatments, associated new costs of medical education and diagnosis, and the need for chronic disease management.

Questions answered by this report include:

What is the actual in-market status of all EU designated orphan drugs with marketing authorisations up to the beginning of 2008?
Which drugs are covered by reimbursement, which are not?
Are special funds available for orphan drugs?
Where is health technology assessment required?
How large is the European price corridor for orphan drugs?
Is there a relationship between target patient population and price?
How do orphan drug policies differ across the leading European countries?
Do payers view all orphan drugs as unique?

Table of Contents : 

Executive Summary

1. Introduction
1.1 What are Orphan Drugs?
1.2 What are the P&R Issues with Orphan Drugs?

2. EU Orphan Drug Regulation
2.1 Objectives
2.2.Qualifying Criteria
2.3 Procedure/Timetable
2.4 Incentives
2.4.1 Information
2.4.2 R&D
2.4.3 Protocol Assistance
2.4.4 Marketing Approval Assistance
2.4.4.1 Priority review/fast track
2.4.4.2 Lower regulatory fees
2.4.5 Market Exclusivity
2.4.5.1 Exclusivity withdrawn?
2.5 Comparison with US Orphan Drug Act
2.6 Results
2.6.1 Designation
2.6.2 Marketing Approval
2.6.3 Medical Benefit
3. Compassionate Use

4. Paediatric Regulation

For more information please contact :

http://www.aarkstore.com/reports/Orphan-Drugs-in-Europe-Pricing-Reimbursement-Funding-and-Market-Access-Issues-1048.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
http://www.aarkstore.com

A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments. Singapore’s Medicines (Orphan Drug) Exemption Order of 1991 was the first legislation anywhere to follow the US Orphan Drug Act, with the other four Asia-Pacific countries also implementing orphan-promoting measures ahead of the EU.

Rare diseases are collectively not that rare, indeed 6-10% of people will suffer from one at some point in life. Asia-Pacific contains nearly two-thirds of the world’s population, and should offer great potential to companies developing orphan drugs. But clinical need alone does not mean that adequate money for diagnosis and treatment will be made available.

The report describes the processes for obtaining orphan product designation, what can be omitted from the standard dossier to obtain marketing authorisation, and provides full details of the regulatory bodies and timelines involved. The main emphasis though is not on registration but on market access, which for products like orphan drugs that often carry premium prices, means eligibility for reimbursement or other sources of public funds.

Based on extensive research, including fieldwork in Tokyo and Seoul in November 2009 to capture detail, understanding and all the latest trends, the report includes:
The incentives on offer to orphan drug sponsors.
How P&R processes work specifically for orphan drugs.
The role of HTA and risk sharing as levers to obtain reimbursement.
Where special funding schemes operate and how to access them.
13 case studies on the P&R history of 12 different orphan drugs in 5 countries.
How much patients are expected to contribute to the cost of their treatment.
Listings of designated and approved orphan drugs.
Comparisons between countries with orphan drug policies and those without.
Contact details of the main rare disease patient organisations.
Learn which of the Asia-Pacific countries …offers the most comprehensive programme for the management of rare disease…often enjoys higher orphan drug prices than the US…has the most orphan drugs on the market and reimbursed…promotes the development of rare disease medical devices as well as drugs…where ‘named patient’ imports are discouraged by rare disease patient representatives.

Table of Contents : 
1. Introduction
2. Japan
2.1 Healthcare and Health Insurance System

2.2 Orphan Drug Legislation

For more information please contact :

http://www.aarkstore.com/reports/Orphan-Drugs-in-Asia-Pacific-From-designation-to-pricing-funding-market-access-39545.html

http://blogs.aarkstore.com/

From:Aarkstore Enterprise
Contact: Neel
Email: press@aarkstore.com
http://www.aarkstore.com

Product Description
Together with the blind fiddler, “Uncle” Dan, Annie squares off against the Chizzler, then embarks on her first novel-length adventure. In a story lasting nearly a full year, Annie’s supposed “real” parents – Boris and Libby Bleek, leaders of the criminal Ghost Gang – gain legal custody of her, while “Daddy” Warbucks is hounded into jail by the unscrupulous politician, Phil O. Bluster. “The One-Way Road to Justice” leaves a penniless Annie and “Daddy” and on the bum amidst the Great Depression. Contains every daily and color Sunday strip from July 10, 1933 through February 10, 1935, printed directly from Harold Gary’s original artwork.

Complete Little Orphan Annie Volume 5

Orphan Drugs in Asia-Pacific: From designation to pricing, funding & market access
 
 It is estimated that 6-10% of the world’s population will suffer from a rare disease at one point in life. On this basis, the markets of Asia-Pacific should offer great potential to companies developing orphan drugs. The region’s population is 4 billion, nearly two-thirds of the global total, so even the rarest disease will have many patients seeking treatment. ( http://www.bharatbook.com/detail.asp?id=133024&rt=Orphan-Drugs-in-Asia-Pacific-From-designation-to-pricing-funding-market-access.html )
 
 But clinical need rarely correlates with affordability, which dictates what is actually spent on healthcare. A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of orphan drugs. Singapore’s Medicines (Orphan Drug) Exemption Order of 1991 was the first legislation anywhere to follow the US Orphan Drug Act, with the other four Asia-Pacific countries also implementing orphan-promoting measures ahead of the EU.
 
 The report describes the processes for obtaining orphan product designation, what can be omitted from the standard dossier to obtain marketing authorisation, and provides full details of the regulatory bodies and timelines involved. The main emphasis though is not on registration but on market access, which for products like orphan drugs that often carry premium prices, means eligibility for reimbursement or other sources of public funds.
 
 Based on extensive research, including fieldwork in Tokyo and Seoul in November 2009 to capture detail, understanding and all the latest trends, the report includes:
 
 * The incentives on offer to orphan drug sponsors.
 * How P&R processes work specifically for orphan drugs.
 * The role of HTA and risk sharing as levers to obtain reimbursement.
 * Where special funding schemes operate and how to access them.
 * 13 case studies on the P&R history of 12 different orphan drugs in 5 countries.
 * How much patients are expected to contribute to the cost of their treatment.
 * Listings of designated and approved orphan drugs.
 * Comparisons between countries with orphan drug policies and those without.
 * Contact details of the main rare disease patient organisations.
 
 Learn which of the Asia-Pacific countries …offers the most comprehensive programme for the management of rare disease…often enjoys higher orphan drug prices than the US…has the most orphan drugs on the market and reimbursed…promotes the development of rare disease medical devices as well as drugs…where ‘named patient’ imports are discouraged by rare disease patient representatives.
 
 
 To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=133024&rt=Orphan-Drugs-in-Asia-Pacific-From-designation-to-pricing-funding-market-access.html
 
 Or
 
 Contact us at :
 
 Bharat Book Bureau
 Tel: +91 22 27578668
 Fax: +91 22 27579131
 Email: info@bharatbook.com 
 Website: www.bharatbook.com 
 Blog: http://bharatbookresearch.blogspot.com
 Follow us on twitter: http://twitter.com/3bbharatbook

The leading business intelligence provider, has released its latest research “The Future of Orphan Diseases Therapeutics – Market Forecasts to 2015, Pipeline Analysis and Reimbursement” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global orphan diseases therapeutics market. The report analyzes the markets for orphan diseases therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, and price are forecast until 2015 for the key geographies as well as select therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and also analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

http://www.visionshopsters.com/product/1247/The-Future-of-Orphan-Disease-Therapeutics-Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
– Annualized market data for the orphan diseases therapeutics market from 2000 to 2008, forecast forward to 2015
– Analysis of the leading therapeutic segments. These include Fabry Disease, Pompe Disease and Mucopolysaccharidosis.
– Analysis of the orphan diseases therapeutics market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain, and Japan
– Market characterization of the orphan diseases therapeutics market including market size, annual cost of therapy, and treatment usage patterns
– Key drivers and barriers that have a significant impact on the market
– Coverage of pipeline molecules in various phases of drug development
– Competitive benchmarking of leading companies. The key companies studied in this report are F.Hoffmann-La Roche, Genzyme Corporation, Novartis AG, Celgene Corporation, Orphan Europe, Pfizer Inc, Actelion Pharmaceuticals and Shire Plc.
– Key M&A activities, licensing agreements, that have taken place between 2008 and 2009 in the global orphan diseases therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to
– Align product portfolio to the markets with high growth potential
– Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth
– Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety
– Develop key strategic initiatives by understanding key focus areas of leading companies
– Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Companies Mentioned

F.Hoffmann-La Roche
Genzyme Corporation
Novartis AG
Celgene Corporation
Orphan Europe
Pfizer Inc
Actelion Pharmaceuticals
Shire Plc.

Table Of Contents :

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Global Orphan Disease Market : Introduction
2.1 Disease Overview
2.1.1 The United States
2.1.2 Europe
2.1.3 Japan
2.2 Report Guidance
2.3 Market Overview
3 Global Orphan Disease Therapeutics Market : Market Characterization
3.1 Market Forecasts
3.2 Orphan Drugs by Disease Sectors
3.3 Usage Patterns
3.3.1 Diseased Population
3.3.2 Treatment Seeking Population
3.3.3 Diagnosis Population
3.3.4 Prescription Population
3.3.5 Therapeutic Usage Patterns
3.4 Geographical Distribution
3.4.1 Market Drivers
3.4.2 Market Restraints
3.5 Key Market Trends
3.5.1 Increase in Federal Funding
3.5.2 Product Pipeline
3.5.3 Regulatory trends – Current Pricing and Reimbursement Scenario
4 Global Fabry Disease Therapeutics Market
4.1 Market Overview
4.2 Market Forecasts
4.3 Average Cost of Therapy
4.4 Usage Patterns
4.4.1 Diseased Population
4.4.2 Treatment Seeking Population
4.4.3 Diagnosis Population
4.4.4 Prescription Population
4.4.5 Therapeutic Usage Patterns
4.5 Product Analysis
4.5.1 Fabryzyme
4.5.2 Replagal
4.6 Drug Pipeline Analysis
5 Global Pompe Disease Therapeutics Market
5.1 Market Overview
5.2 Market Forecasts
5.3 Average Cost of Therapy
5.4 Usage Patterns
5.4.1 Diseased Population
5.4.2 Treatment Seeking Population
5.4.3 Diagnosis Population
5.4.4 Prescription Population
5.4.5 Therapeutic Usage Patterns
5.5 Product Analysis
5.5.1 Myozyme
5.6 Pipeline
6 Global Mucopolysaccharidosis VI Disease Therapeutics Market
6.1 Market Overview
6.2 Market Forecasts
6.3 Average Cost of Therapy
6.4 Usage Patterns
6.4.1 Diseased Population
6.4.2 Treatment Seeking Population
6.4.3 Diagnosis Population
6.4.4 Prescription Population
6.4.5 Therapeutic Usage Patterns
6.5 Product Analysis
6.5.1 Naglazyme
7 The US Orphan Disease Therapeutics Market
7.1 Market Overview
7.2 Market Forecasts
7.3 Usage Patterns
7.3.1 Diseased Population
7.3.2 Treatment Seeking Population
7.3.3 Diagnosis Population
7.3.4 Prescription Population
7.3.5 Therapeutic Usage Patterns
8 Europe Orphan Disease Therapeutics Market
8.1 Market Overview
8.2 Market Forecasts
8.3 Usage Patterns
8.3.1 Diseased Population
8.3.2 Treatment Seeking Population
8.3.3 Diagnosis Population
8.3.4 Prescription Population
8.3.5 Therapeutic Usage Patterns
9 Japan Orpahn Disease Therapeutics Market
9.1 Market Overview
9.2 Market Forecasts
9.3 Usage Patterns
9.3.1 Diseased Population
9.3.2 Treatment Seeking Population
9.3.3 Diagnosis Population
9.3.4 Prescription Population
9.3.5 Therapeutic Usage Patterns
10 Global Orphan Disease Therapeutics Market : Competitive Landscape
10.1 Overview
10.2 Competitor Profiling
10.2.1 Genzyme Corporation
10.2.2 Celgene Corporation
10.2.3 Actelion Pharmaceuticals
10.2.4 Shire Pharmaceuticals
10.2.5 AstraZeneca
10.2.6 Boehringer Ingelheim
10.2.7 Bristol-Myers Squibb
10.2.8 GlaxoSmithKline (GSK)
10.2.9 Novartis
10.2.10 Pfizer
10.2.11 Eli Lilly
10.2.12 Sanofi Aventis
10.2.13 UCB Pharma
10.2.14 Wyeth
11 Pipeline Analysis
11.1 Autoimmune Disorders
11.1.1 Cellcept
11.1.2 Pirfenidone
11.1.3 Rituxan
11.2 Genetic Disorders
11.2.1 Denufosol tetrasodium inhalation solution(INS37217)
11.2.2 Bronchitol(Mannitol)
11.2.3 Catena (Idebenone)
11.3 Infectious Diseases
11.3.1 XP-28 (xepol)
11.4 Neurology
11.4.1 Cladribine
11.4.2 Clazosentan (Pivlaz®)
11.5 Respiratory Disorders
11.6 Transplantation
11.7 Cardiovascular Disorders
11.7.1 ISIS 301012(Mipomersen sodium)
11.8 Cancer
11.8.1 Avastin
11.8.2 Enzastaurin
11.8.3 Patupilone
11.8.4 Zactima
11.8.5 Genasense
11.8.6 Ipilimumab (MDX-010, MDX-101)
11.9 Blood Cancer
11.10 Skin Cancer
11.11 Other Disorders
12 Global Orphan Disease Therapeutics Market: Strategic Consolidations
12.1 Mergers and Acquisitions
12.1.1 Genzyme Corp. and Bioenvision, Inc.
12.1.2 ViroPharma and Lev Pharmaceuticals
12.1.3 Biovitrum and Swedish Orphan
12.1.4 Shire plc and Zymenex A/s
12.2 Licensing Agreements
12.2.1 Overview
12.2.2 Drug Discovery & Preclinical
12.2.3 Phase I
12.2.4 Phase I
12.2.5 Phase III
12.2.6 Approved
13 Appendix
13.1 Market Definitions
13.2 Key Support Data
13.3 Abbreviations
13.4 Research Methodology
13.4.1 Coverage
13.4.2 Secondary Research
13.4.3 Primary Research
13.4.4 Forecasts
13.5 Expert Panel Validation
13.6 Contact Us
13.7 Disclaimer

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/1247/The-Future-of-Orphan-Disease-Therapeutics-Market-Forecasts-to-2015-Pipeline-Analysis-and-Reimbursement.html

Contact us:

Visionshopsters
Ph : 91-22-40583000
Emailid: marketing@visionshopsters.com
Website : www.visionshopsters.com